

AusVaxSafety goes to school

Monitoring 9-valent HPV vaccine safety
via school-based immunisation

*Alexis Pillsbury, Helen Quinn, Catherine Glover, Chloe Damon,
Alan Leeb and Kristine Macartney
on behalf of the AusVaxSafety Consortium*



Australia's active vaccine safety surveillance system



Nationwide
(250+ sentinel sites)



Participant-based
(~70% participation rate)



SmartVax: automated
data collection

And for the first time...

SmartVax



**AusVaxSafety utilises
school-based immunisation programs
to monitor safety of 9vHPV vaccine**



Compare rates of adverse events reported by adolescents aged 10-15 years receiving 4vHPV or 9vHPV vaccine

4 _v HPV	1 Feb-13 May	2017
9 _v HPV	1 Feb-13 May	2018



Participant details



NIP vaccine



Participants



Sex




Median age



*% Aboriginal/
Torres Strait Islander*

2017	4vHPV (Gardasil)	3,874/5,756 (67.3%)	51.3% female	12 years	3.5%
2018	9vHPV (Gardasil9)	6,205/9,180 (67.6%)	49.5% female	12 years	1.7%

Participant details



*Concomitant vaccine
received*



Any adverse event



*Medically attended
adverse event*

2017
Gardasil

79.4%

8.1%

0.7%


2018
Gardasil9

92.5%

10.1%

0.6%

Adverse events reported by vaccine/year



Rates low and within expected ranges





Why does this surveillance matter?



- Australia has led the world in HPV vaccination
 - High coverage
 - Impact is being observed
- AusVaxSafety Active provides early, brand-specific safety data





Acknowledgements



www.AusVaxSafety.org.au